On June 15, 2022, KPMG China releases the list of "the First Top 50 Biotechnology Innovation Enterprises 2022". With its excellent innovation strength and development potential, BriSTAR Immunotech Limited is successfully included into the list through screening and evaluation by KPMG China and industry experts after about 10 months. In addition, Dr. Pan Guohua, CEO of BriSTAR Immunotech Limited, is invited to participate in the cloud table talks to discuss the current innovation and future development trend of biomedical enterprises with other guests.

The First KPMG China Top 50 Biotechnology Innovation Enterprises 2022 is hosted by KPMG China, with five major selection criteria such as pioneering technology and product pipelines, the backgrounds of core management team and R & D team, the influence in the capital market, the diversity of product pipelines, and good financial status. The event aims to select leading biotechnology innovation enterprises and to establish a resource sharing platform for biotechnology enterprises, so as to help biotechnology enterprises at all stages of development to increase their influences in the market, and to aid the listed enterprises to grasp policy and capital market development opportunities, so that they will realize organic growth. After several rounds of selections, BriSTAR Immunotech Limited is successfully listed as one of the first top 50 biotechnology innovation enterprises.

In addition, Dr. Pan expresses that innovation is the lifeline of an enterprise during the review and prospect of BriSTAR Immunotech Limited's current biotechnology industry at the cloud table talks, and he hopes to establish an innovation ecosystem within the industry and among enterprises to set up a better innovation system. In BriSTAR Immunotech Limited's biomedicine industry, especially in the global emerging treatment fields of cell therapy and gene therapy, he believes that catching up with the international leading level is very promising. In addition, utilizing innovative technology to assist drug development will help innovative drug enterprises in reducing costs and improving the efficiency of drug development. Furthermore, in the current industry environment full of both opportunities and challenges, biomedical enterprises will develop forward-looking and different R&D strategies and diversify product pipelines, so that innovative drugs will benefit patients as soon as possible, which will help Chinese biomedical enterprises top among the world.